Literature DB >> 7973224

Stopping when the experimental regimen does not appear to help.

S Wieand1, G Schroeder, J R O'Fallon.   

Abstract

We discuss a procedure that offers the possibility of reducing the number of patients assigned to experimental regimens which are no more effective than a standard regimen. The procedure is useful in advanced cancer trials in which the length of the accrual period might be more than twice the median survival time for the standard regimen. The procedure is intuitively appealing and offers a 50 per cent chance of stopping accrual to ineffective therapies, yet is associated with a loss of power of less than 0.02.

Entities:  

Mesh：

Year:  1994        PMID： 7973224     DOI： 10.1002/sim.4780131321

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


  20 in total

1.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

2.  Optimal two-stage log-rank test for randomized phase II clinical trials.

Authors:  Minjung Kwak; Sin-Ho Jung
Journal:  J Biopharm Stat       Date:  2016-04-06       Impact factor: 1.051

3.  Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Natl Cancer Inst       Date:  2017-06-01       Impact factor: 13.506

4.  Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2018-06-27       Impact factor: 44.544

5.  Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma.

Authors:  William G Breen; S Keith Anderson; Xiomara W Carrero; Paul D Brown; Karla V Ballman; Brian P O'Neill; Walter J Curran; Ross A Abrams; Nadia N Laack; Ralph Levitt; Evanthia Galanis; Jan C Buckner; Edward G Shaw
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

6.  Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance).

Authors:  Nadine J McCleary; Joleen Hubbard; Michelle R Mahoney; Jeffrey A Meyerhardt; Daniel Sargent; Alan Venook; Axel Grothey
Journal:  J Geriatr Oncol       Date:  2017-09-13       Impact factor: 3.599

7.  Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

Authors:  Paul A DiSilvestro; Shamshad Ali; Peter S Craighead; Joseph A Lucci; Yi-Chun Lee; David E Cohn; Nicola M Spirtos; Krishnasu S Tewari; Carolyn Muller; Walter H Gajewski; Margaret M Steinhoff; Bradley J Monk
Journal:  J Clin Oncol       Date:  2014-01-06       Impact factor: 44.544

8.  Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.

Authors:  Arkadiusz Z Dudek; Xiaofei Wang; Lin Gu; Stephanie Duong; Thomas E Stinchcombe; Robert Kratzke; Hossein Borghaei; Everett E Vokes; Hedy L Kindler
Journal:  Clin Lung Cancer       Date:  2020-07-03       Impact factor: 4.785

9.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

10.  The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Authors:  Benjamin R Saville; Jason T Connor; Gregory D Ayers; JoAnn Alvarez
Journal:  Clin Trials       Date:  2014-05-28       Impact factor: 2.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.